Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Allergan : to Report Third Quarter 2017 Earnings and Host Conference Call and Webcast

share with twitter share with LinkedIn share with facebook
share via e-mail
10/04/2017 | 10:25am CEST

Release date- 03102017 - DUBLIN - Allergan plc (NYSE: AGN) today announced it intends to release third quarter 2017 financial results on Wednesday, November 1, 2017, prior to the open of the U.S. Financial Markets.

Allergan will host a conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, November 1, 2017 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the conference ID is 65879759.

A taped replay of the conference call will also be available beginning approximately two hours after the call's conclusion, and will remain available through 11:30 p.m. Eastern Time on December 1, 2017. The replay may be accessed by dialing (855) 859-2056 and entering the conference ID 65879759. From international locations, the replay may be accessed by dialing (404) 537-3406 and entering the same conference ID.

To access the webcast, please visit Allergan's Investor Relations website at ttps://www.allergan.com/inves.... A replay of the webcast will also be available on Allergan's Investor Relations website.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model - Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs currently in development.

Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan'scurrent perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDAapprovals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2017. Except as expressly required by law, Allergandisclaims any intent or obligation to update these forward-looking statements.


Daphne Karydas

Tel: (862) 261-8006

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ALLERGAN PLC
07/12ALLERGAN : An Application for the Trademark "VESSILA" Has Been Filed by Allergan
07/12Novartis Becomes Latest Player to Exit Antibiotic, Antiviral Research
07/12ALLERGAN : Expands REFRESH Portfolio With New REFRESH REPAIR Lubricant Eye Drops
07/11ALLERGAN : Forbion raises EUR 270M, surpassing target for fourth fund
07/10ALLERGAN : Expands REFRESH® Portfolio With New REFRESH® REPAIR Lubricant Eye Dro..
07/06ALLERGAN : Study in Chronic Migraine Receives Migraine Research Award at the Ame..
07/05ALLERGAN : An Application for the Trademark "ANDRODERM" Has Been Filed by Allerg..
06/29ALLERGAN : Eases Manual Data Entry and Contract Management Pains with Pramatas B..
06/28ALLERGAN : An Application for the Trademark "ANDRODERM" Has Been Filed by Allerg..
06/28ALLERGAN : Study in Chronic Migraine Receives Migraine Research Award at the Ame..
More news
News from SeekingAlpha
07/19Allergan (AGN) Abicipar SEQUOIA & CEDAR Phase 3 Study Results - Slideshow 
07/19Big Pharma in the red on ramped up pressure on drug prices 
07/19Allergan's abicipar on par with Lucentis in two late-stage AMD studies; share.. 
07/18Madrigal Is Unreasonably Priced For Perfection And Limited Competition 
07/18FDA committed to easing approval path for biosimilars 
Financials ($)
Sales 2018 15 306 M
EBIT 2018 7 381 M
Net income 2018 -1 152 M
Debt 2018 23 173 M
Yield 2018 1,56%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,41x
EV / Sales 2019 5,09x
Capitalization 59 560 M
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 207 $
Spread / Average Target 18%
EPS Revisions
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC7.38%59 560
JOHNSON & JOHNSON-7.59%346 292
PFIZER3.95%220 236
ROCHE HOLDING LTD.-4.77%200 995
NOVARTIS-2.11%200 139
MERCK AND COMPANY11.85%168 225